Fast Track Designation News, Researches, Clinical Trials and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Powered by Hostinger

Latest Articles

Satellos Receives FDA Fast Track Designation for SAT-3247 in Duchenne Muscular Dystrophy

Press Releases June 29, 2026 0

Satellos Bioscience has announced that the U.S. Food and...

Elixirgen and Nippon Shinyaku Partner on Full-Length Dystrophin Therapy for Duchenne

Press Releases June 26, 2026 0

Elixirgen Therapeutics has announced a strategic option agreement with...

REGENXBIO Completes RGX-202 Confirmatory Study for Duchenne Muscular Dystrophy

Press Releases June 24, 2026 1

REGENXBIO has announced the completion of patient dosing in...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Therapies December 26, 2024 4

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 9

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 2

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

Fast Track Designation

Must Read

Duchenne Muscular Dystrophy Treatment Access: A Global Failure of Equity, Policy, and Accountability

Medera’s Gene Therapy for DMD Cardiomyopathy Gains Momentum with FDA Fast Track Designation

Effects of Exon Deletions and Isoform Deficiencies in Duchenne Muscular Dystrophy